<unk>  is a fixed-dose combination of<unk> , a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor, and<unk> , an HCV NS5A inhibitor that is FDA approved for the treatment of adult patients with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection (1) without cirrhosis or with compensated cirrhosis or with decompensated cirrhosis for use in combination with ribavirin. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include fatigue, anemia, nausea, headache, insomnia, and diarrhea.
Sofosbuvir / velpatasvir
Ledipasvir / sofosbuvir
Dolutegravir / rilpivirine
Ombitasvir / paritaprevir / ritonavir / dasabuvir
Elbasvir / grazoprevir
Glecaprevir / pibrentasvir
Bictegravir / emtricitabine / tenofovir alafenamide
Lopinavir ritonavir